Goldman Sachs analyst Asad Haider upgraded Dentsply Sirona to Conviction Buy from Buy with a $66 price target. The analyst sees "several meaningful earnings drivers" coming together for 2020. Primescan demand appears durable, the OneDS program should drive incremental market share, and the company's restructuring is tracking ahead of plan, Haider tells investors in a research note. Further, despite Dentsply's 54% rally year-to-date, the stock still trades slightly below the median of mature medtech companies despite a stronger forward earnings outlook, adds the analyst.